Sirionbiotech Press Releases

New success for SIRION Biotech vaccination candidate Ad19a/64


New success for SIRION Biotech vaccination candidate Ad19a/64


Sirion Logo

Press Release | SIRION Biotech GmbH

DECEMBER 12, 2016

Martinsried, Germany: – Viral vector specialist SIRION Biotech’s latest adenovirus serotype Ad19a/64 has reinforced its credentials as a promising vaccination candidate by scoring top marks in a prime boost experiment.

Oncology specialists consider Ad19a/64 to form a promising vaccination and immune oncology tool because it transduces human dendritic cells and myoblasts better than standard adenoviral serotypes.

In October 2016, SIRION reported that using Ad19a to express an antigen had elicited solid immunization in mice, even among animals pre-immunized against common Ad serotypes.

Powerful prime reagent

Now results from a later study have demonstrated that Ad19a/64 vectors can also act as a powerful prime reagent in a two-step prime boost vaccination approach.

In this experiment, animals were first treated with antigen-expressing Ad19a/64. Given alone, this already elicits a solid increase of IFNg and TNFa positive T-cells in the spleen of the animals, indicating immunization. Five weeks after this prime, a secondary boost by DNA vectors was administered. This led to an added increase of marker-positive T-cells by a factor of 20.

POC study

“The synergistic effect of Ad19a/64 combined with a second vector system underline its value as a high potential vaccination candidate to treat a number of yet unmet needs,” said SIRION Biotech CEO, Dr. Christian Thirion.

“Further studies by leading scientific groups are currently being conducted, including a vaccination trial in non-human primates and a proof of concept (POC) study to establish an immune oncology platform,” Dr. Thirion added.

Initial results from the new studies are expected in early January 2017.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational lentiBOOSTTM for high efficiency transduction hematopoietic stem cells and T-cells – even in clinical applications.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo situation. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

Media Contacts

Dr. Carl J. Christel, Senior Manager for Sales and Marketing, SIRION Biotech GmbH
Tel: +49-89-700 961 99-18
Email: christel@sirion-biotech.com

Resources

Click on New success for SIRION Biotech vaccination candidate Ad19a/64 for other information.
Click on SIRION to contact the company directly.
Click on Ad19a/64 for detailed information on new serotype.

Ad19a/64 raises levels of common markers (red circles) beyond immunization threshold. Application of secondary DNA based boost vectors five weeks after the prime increased the effect by a factor 20 (blue squares)..

Ad19a/64 raises levels of common markers (red circles) beyond immunization threshold. Application of secondary DNA based boost vectors five weeks after the prime increased the effect by a factor 20 (blue squares)


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study


SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study


Sirion Logo

Press Release | SIRION Biotech GmbH

OCTOBER 13, 2016

Martinsried, Germany: – Viral technology specialist SIRION Biotech’s latest adenovirus serotype Ad19a/64 has passed a further significant milestone in its validation process as a novel vaccination candidate.

New in vivo results in mice, recorded in a laboratory study conducted by world-renowned researcher Prof. Peter Holst of the University of Copenhagen, have clearly shown that this new serotype elicits comparable immune reactions against a given antigen as effective as Ad5, even in animals that were pre-immunized against the Ad5 serotype.

Adenovirus vectors

“The study underlined the importance of Ad19a/64 development into a vaccination vehicle to solve the problem of pre-immunized populations,” commented SIRION Biotech CEO Dr. Christian Thirion.

“We already knew that pre-immunisation rates against our novel Ad19a/64 are very low in human populations, an important trait for a future vaccination candidate.” he explained.

“But we were not sure whether pre-acquired immunity against the common Ad5 might generate a cross-reaction. This study seems to have removed that uncertainty,” said Dr. Thirion.

HPV clinical testing

As a next step, SIRION Biotech will now enter first pre-clinical testing of the Ad19a/64 vector system in non-human primates to cure human papillomavirus (HPV).

Adenovirus vectors enable the direct introduction of genetic antigen information into patients instead of inoculating them with inactivated pathogen. This method of direct antigen presentation is thought to hold the solution for a number of diseases currently unanswered by standard vaccination methods.

Ad19a/64 has been considered highly promising in this context because it transduces human myoblasts and dendritic cells better than any other serotype.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel.: +49-89-700 961 99-15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study for other information.
Click on SIRION to contact the company directly.
Click on Ad19a/64 for detailed information on new serotype.

Mice were treated with Ad5 or Ad19a/64 vectors carrying the genetic code for a defined antigen as vaccination target. In two groups (Triangles and diamonds) the animals received a round of Ad5 particles before the treatment.  Immunization success 10 days post-application was measured by determining IFNg+ levels in the spleens of all animal groups. Pre-immunization against Ad5 shut down its performance (diamonds), while Ad19a/64 was undisturbed by the pre-immunization event

Mice were treated with Ad5 or Ad19a/64 vectors carrying the genetic code for a defined antigen as vaccination target. In two groups (Triangles and diamonds) the animals received a round of Ad5 particles before the treatment. Immunization success 10 days post-application was measured by determining IFNg+ levels in the spleens of all animal groups. Pre-immunization against Ad5 shut down its performance (diamonds), while Ad19a/64 was undisturbed by the pre-immunization event


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16


SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16


Sirion Logo

Press Release | SIRION Biotech GmbH

OCTOBER 10, 2016

Martinsried, Germany: – Viral technology specialist SIRION Biotech will be returning to ELRIG for its 10th Anniversary Drug Discovery (ELRIG-DD16) conference in Liverpool, UK (October 13th-14th).

The company will be posting its latest insights and advances on its LV, AAV and AV viral vector technologies along with presentations on its advanced vector engineering platform VariCHECK, optimized and re-targeted viral vectors for cell-based therapy as well as research- and clinical grade transduction enhancer LentiBOOSTTM to efficiently transduce primary and hard to target cells.

SIRION’s team will include Dr. Franziska Ruf, Key Accounts Manager for Europe and Dr. Cristina-Ileana Ureche, newly appointed Key Account Manager for Asia.

SIRION is inviting all ELRIG-DD16 delegates to contact the company and set up face-to-face meetings with Dr. Ruf or Dr. Ureche during the conference in Liverpool, UK.

Dr. Franziska Ruf, who will present the poster on VariCHECK, commented:

“Why do I care about viral vectors? Simply because engineered viral vectors are not only perfect tools for functional gene analyses and target research but also transform our understanding of disease, becoming new innovative medicines. ”

“SIRION has been a participant at the ELRIG Drug Discovery conferences for several years now. This is an excellent platform to share our knowledge with fellow scientists and company representatives working in cell based research areas like early drug discovery, gene/cell-based therapy and regenerative medicine ,” said Dr. Ruf.

“We’ll be able to show how in gene therapy we are now achieving the highest LV and AAV T-cell transduction rates on the market and how we are using leading vector engineering and capsid optimization to increase tissue specificity and improve immunogenic profile,” added Dr. Cristina-Ileana Ureche.

About SIRION Biotech

In business since 2007 and based near Munich in Germany, SIRION BIOTECH is Europe’s leading commercial supplier of tailored viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

SIRION’s mission is to change the paradigm for viral vector supplies, with its ability to develop and supply all common viral vector types (adenovirus, lentivirus and AAV) in highest quality within a matter of weeks.

The company also offers a full range of virus related products and services, ranging from transduction enhancer agents to fully customized cell models including the transformative RNAiONE™ knockdown validation platform.

With this comprehensive viral vector portfolio, SIRION offers a suitable option for almost any preclinical in vitro and in vivo application.

About ELRIG DD16

The European Laboratory Research & Innovation Group (ELRIG) is a UK-based not-for-profit organization serving the needs of the drug discovery and life science communities across Europe. ELRIG’s flagship event, “Drug Discovery” now attracts more than 1,300 delegates, making it the biggest conference of its kind in Europe.

The 10th anniversary Drug Discovery ’16 is a two-day event, opening October 13 at the Echo Arena (ACC) in Liverpool. The conference will feature more than 50 speakers over six session tracks focusing on Innovations in Chemistry, Oncology & Immunology, Innovations in Predictive & Translational Models, Assay Development, Screening & Emerging Technologies, Cells and Genes in Therapy and Diagnostics and Target Identification & Validation. The conference will also feature an exhibition, as well as a new feature, interactive Core Technologies Workshops & Vendor Tutorials.

More information at: http://elrig.org/portfolio/drug-discovery-2016/

Media Contacts

Dr. Franziska Ruf; Manager, Key Accounts Europe, SIRION Biotech GmbH
Email: ruf@sirion-biotech.de

Resources

Click on SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16 for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume


SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume


Sirion Logo

Press Release | SIRION Biotech GmbH

JULY 19, 2016

Martinsried, Germany: – German publisher Springer Protocols has issued volume on lentiviral vector (LV) protocols for gene engineering that also includes innovative advances made by Munich-based SIRION Biotech.

The latest volume in the Springer series on ‘Methods in Molecular Biology’ addresses “Lentiviral Vectors and Exosomes as Gene and Protein Tools” in which leading scientists in the field of gene editing describe novel approaches based on lentivirus technology.

In the new volume, Maurizio Federico of the National AIDS Center in Rome, Italy, presents 19 such approaches ranging from LV construction over LV targets and applications over integrase-mutant LV’s to the engineering of exosomes.

Moving to industrial applications

Contributors also include Axel Schambach of Hannover Medical School, and David Fenard of French Généthon in Evry and Natasa Anastasov at Munich’s Helmholtz Center of Radiation Biology.

Also described are new lentiviral transduction methods using poloxamers as reagents, spinoculation and scFv-antibody fusions to VSV-G that increase viral performance more than tenfold, with the potential to improve clinical protocols.

SIRION Biotech is a pioneer in customizing Lentivirus to enhance their application spectrum in research and development. Hundreds of viral vector based methods are in or on the verge of clinical testing, making this relatively new class of biologicals as exciting and promising as antibody technologies 30 years ago.

About SIRION Biotech
SIRION Biotech was founded at Martinsried, near Munich, in 2007, with the vision of developing next generation viral vectors for gene therapy and vaccines and enabling the creation of novel cell models closer to reality than ever before. This required the assembly of a comprehensive viral vector platform.

Since then, SIRION has become an international leader in innovating virus vector technologies, providing custom services to academic and industrial partners worldwide. Its core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application.

SIRION is now Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies. It is also the only company to master all three major virus types that are used regularly for genetic manipulation of cell systems: all-in-one Lentivirus, adeno-associated viruses (AAVs) and Adenovirus vectors.

SIRION’s technologies have been validated in over 500 single projects with more than 150 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel: +49 89 700 961 99 15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume for other information.
Click on SIRION to contact the company directly.
Click on Lentiviral Vectors to see abstract of the volume.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech expands business and ideas


SIRION Biotech expands business and ideas


Sirion Logo

Press Release | SIRION Biotech GmbH

FEBRUARY 23, 2016

Munich, Germany: – Viral technology specialist SIRION Biotech has reported revenues almost doubled during the last financial year as well as major new collaboration and licensing deals.

These developments consolidate SIRION’s pole position as a leading force in gene delivery technologies and hi-tech developer of viral vector technologies, catering to the life sciences.

During the second half of 2015, SIRION Biotech concluded landmark deals with global pharma companies to develop and license next-generation gene delivery techniques.

Moving to industrial applications

These deals all reflect growing interest in novel therapies and vaccines that use viral gene delivery tools as bases for curative therapies.

“The company has entered new territory by also specializing in industrial uses of its technologies, in addition to drug discovery and early R&D applications,” commented SIRION Biotech’s Managing Director, Dieter Lingelbach.

“The fact that we struck major deals in both sectors last year means that virus-based delivery is in the process of becoming a routine commercial application, very much like antibodies did about 20-30 years ago,” added Mr. Lingelbach.

Collaborative partnerships

As specialists for the design and engineering of viral vectors SIRION Biotech will collaborate closely with its Pharma- and Biotech-partners to engineer specific gene delivery systems to accurately fit in the context of their therapeutic developments. The projects will be built from a preclinical base upwards, maintaining active collaboration well into the clinical phases.

“With SIRION at their sides, our partner companies will be able predict and address the roadblocks laid out by the complex nature of modern gene applications and take these hurdles in stride,” said Dr. Carl J. Christel, SIRION’s Senior Manager of Sales & Marketing.

“In the end this joint approach will help create and refine new technologies to be implemented in a wide array of gene replacement therapies, cancer immunotherapies and genetic vaccination approaches,” says Dr. Christel.

Expanding research boundaries

SIRION has also turned to a form of crowd sourcing to influence its future development pipeline.

With a whole list of AAV engineering projects for 2016, SIRION is pushing the boundaries of in-vivo gene modification to enable highest possible expression control.

Now it has appealed for ideas from partners and researchers visiting its website for their ideas as to which tissue or cell types are the most interesting research candidates to be included in its R&D program.

“This is your chance to influence our AAV program.” the company says.

The current SIRION AAV-R&D pipeline includes optimized AAV serotypes to target specific cell types and tissues, including endothelial AAV, inducible AAV expression vectors and AAV transduction boosters to maximize transduction efficiencies.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become an international leader in innovating virus vector technologies, providing custom services to academic and industrial partners worldwide. Its core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application.

SIRION is now Europe’s leading supplier of viral vectors used for genetic research, target validation, gene therapy and vaccination studies. It is also the only company to master all three major virus types that are used regularly for genetic manipulation of cell systems: All-in-one Lentivirus, adeno-associated viruses (AAVs) and adenovirus vectors.

SIRION offers a range of advanced technologies including control gene expression and knockdown, inducible, tissue specific expression and transduction boosters, as well as a full range of virus related services, ranging from particle production to virus driven cell modeling.

Media Contacts

Dr. Carl J. Christel, Sales & Marketing, SIRION Biotech GmbH
Tel: +49 89 700 961 99 18 (Europe)
Tel: +1 857 284 1844 (North America)
Email: christel@sirion-biotech.com

Resources

Click on SIRION Biotech expands business and ideas for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech announces preclinical vaccination success


SIRION Biotech announces preclinical vaccination success


Sirion Logo

Press Release | SIRION Biotech GmbH

JANUARY 11, 2016

Martinsried, Germany: – Viral technology specialist SIRION Biotech has opened the New Year by announcing its first successful preclinical vaccination results from ProVector™ cell products, clearing a pathway to future clinical applications.

SIRION has used its new ProVector™ cell line to increase production of demanding virus constructs, successfully engineering and producing new vaccination vectors based on the adenoviral serotype Ad19a.

The company has collaborated with Prof. Peter J. Holst of the Novo Nordisk Foundation for Basic Metabolic Research at University of Copenhagen to test these new vaccination vectors in rodents.

Outstanding T-cell activation

“Results rose above all expectations,” said SIRION Biotech CEO Dr. Christian Thirion.

“T-cell activation showed an increase against pathogen antigen that not only matched but exceeded responses generated with standard vector systems,” Dr. Thirion explained.

“These promising results lay the groundwork for development of the Ad19a system as the newest openly available vector platform for vaccination R&D. Providing similar results in the next animal system, first clinical applications may be expected as soon as 2017,” he added.

Viral vector technologies

Traditional vaccines are built from inactive or attenuated elements of a pathogen. Viral vectors on the other hand work as DNA or RNA transporters to reprogram a patient’s cells in order to produce a particular antigen and present it directly to the immune system.

This method favors a cell-mediated immune response that fortifies the vaccination success. It also increases the medical potential as it can help fight established disease or cancers as a new form of therapy, on top of serving as a preventative measure.

From a commercial standpoint, viral vectors can help eliminate complex manufacturing processes of classic vaccines and avoid secondary and tertiary structural deviations that are common in synthetic antigen production.

AD19a: preventative vaccination hopes

Ad19a is the latest in adenoviral (AV) gene vector innovations. Demonstrating its ability to elicit robust immune response against a genetically coded antigen in a rodent model, together with a new production cell line that caters to special requirements of complex gene vectors, addresses several challenges of modern vaccination R&D. Hopes are high that it will pave the way to create preventative vaccinations as well as new cancer therapies that will benefit a big segment of the population.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel: +49-89-700 961 99-15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech announces preclinical vaccination success for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe


SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe


Sirion logo

Press Release | SIRION Biotech GmbH

OCTOBER 29, 2015

Martinsried, Germany: – Viral technology specialist SIRION Biotech will bring details of its breakthrough vaccines to November’s prestige BIO-Europe biotechnology partnering conference in Munich.

The SIRION team, led by CEO Dr. Christian Thirion, will show how its new production cell lines have managed to produce high yields of its novel DNA viral vectors associated with toxic antigens, which have hitherto been difficult to express.

Breakthrough vaccines

“We believe our work means that very soon will there be novel breakthrough vaccines in the market,” said. Dr. Thirion.

“Associating vaccines with just prophylaxis will soon be a paradigm of the past. Increasingly, vaccines will demonstrate therapeutic effects specifically in the field of so far difficult to address tumor diseases and immune therapies,” he commented.

HEK293 genetic modification

A critical hurdle has in the past been making enough of the vaccine vector material. This is especially difficult when the viral or bacterial origin of antigens makes them potentially toxic, as is the case with the majority of HIV envelope proteins and bacterial virulence factors.

Over a two-year development project, SIRION Biotech has applied genetic modification to widespread and inexpensive HEK293 cells to suppress specific antigen production. This novel cell line overcomes production issues related to all DNA-based viral vectors that express toxic proteins during the process. The technology is generally applicable to the production of DNA-vector based vaccines and can be applied to common vaccine production cell lines.

Cancer immune therapies

SIRION Biotech has combined its new antigens with innovative invariant chain adjuvant technology developed by Prof. Peter Holst of University of Copenhagen in the quest for novel cancer immune therapies.

The co-development has been based on SIRION’s lead candidate Ad19a as novel adenovirus serotype with promising immune response-stimulating activity. A preclinical safety and efficacy study will soon evaluate a treatment vaccine based on this technology against established HPV infections.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

About BIO-Europe 2015

The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2015 event is a three-day event opening November 2 at Munich’s ICM international conference center.

BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.

This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.

Partnering at BIO-Europe 2015 is powered by EBD Group’s partnering ONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.

More information at: www.ebdgroup.com/bioeurope/index.php

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel: +49-89-700 961 99-15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/